Jiangsu pharmaceutical enterprises three giants hold the group to dominate the 10 billion market!

recently, Enhua Pharmaceuticals announced its first half 2019 results, revenue and net profit both rose sharply, the first half of operating income exceeded the 2 billion mark for the first time, a growth rate of 12.41 percent, net profit of 322 million yuan, a growth rate of 22.87 percent. Enhua Pharmaceuticals said that under the new bidding model of drug centralized belt procurement, the market development and bidding work of the products included in the collection in the non-collection pilot areas has been increased, so that the sales revenue of the collected products has maintained a relatively stable growth. Some time ago, Enhua Pharmaceuticals in Jilin Province to take the initiative to reduce the 4 plus 7 varieties of hydrochloric acid right metomy fixed injection price, this move also confirmed the company's strategy.
Jiangsu's three major pharmaceutical companies dominate the 15 billion psychosetting drug marketFigure 1: China's public medical institutions terminal chemical psychostatity drug sales (units: 10,000 yuan)(Source: Minet China's public medical institutions terminal competition pattern)according to Mi Intranet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal, the market size of psychosetting drugs has exceeded 10 billion yuan since 2016, the annual growth rate of sales has been maintained at more than 10%, in 2018 rose to nearly 15 billion yuan.
Figure 2: China's public medical institutions terminal chemical psychostant TOP3 enterprise market share situation(Source: Minet China's public medical institutions terminal competition pattern)From the competitive situation of enterprises, TOP3 enterprises are Howson Pharmaceuticals, Hengrui Pharmaceuticals and Enhua Pharmaceuticals, all three are star pharmaceutical companies in Jiangsu Province, TOP3 enterprises total market share of more than 40%. AstraZeneta and Xi'an Jansen came in fourth and fifth place, with market share of 6.69% and 5.60% respectively in 2018.
Howson Pharmaceuticals and Hengrui Pharmaceuticals are the main force in the terminals of China's public medical institutions for anti-tumor drugs, and psychostates account for 21.32% of Haussen Pharmaceuticals and 11.05% of Hengrui Pharmaceuticals. In the sub-pattern of Enhua Pharmaceuticals, the proportion of psychostation drugs is close to 58%, and the concentration in the field of mental stability is higher.
Enhua's half-year revenue broke 2 billion, 4 major psychostated drugs consistency evaluation in the process ofTable 1: 2019 first half of Enhua Pharmaceuticals' main products performance(Source: Listed Companies Semi-Annual Report)According to
half-yearly report, Enhua Pharmaceuticals' operating income in the first half of 2019 was RMB2,097 million, up 12.41% YoY, and net profit was RMB322 million, up 22.87% YoY. Subdivided into major products, anesthesia, psychoseient, neurologic products have increased significantly in revenue, gross margin has also increased by about 2% to 3%.
Table 2: First half of 2019 Enhua Pharmaceutical product declaration(Source: Minet MED China Drug Review Database 2.0)In February 2019, Enhua Pharmaceuticals' Lipe ketone tablet (1mg) became the company's first over-evaluation product, opening a new chapter in Enhua Pharmaceuticals' consistent evaluation work. Minenet data show that the current review of the approval of the consistency evaluation products include chlorovine flat tablets, hydrochloric acid right metomeddine injection, lipidone dispersion tablets, gaba spray capsules, Mida zolun injections, of which 4 are psychostated drugs, it can be seen that Enhua Pharmaceuticals for the main area of concern. According to the semi-annual report data, Enhua Pharmaceuticals next has two consistent evaluation projects to be declared, namely, the anti-epileptic drug chlor nitrate tablets and anaesthetic injection of hydrochloric acid refentanyl.
In terms of generic drugs, the painkiller fentanine oral mucous membrane patch, hydrochloric acid he sprayed with more slow release tablets 3 imitations, anti-epileptic drug Pribarin capsule 4 imitations are in the review and approval, in addition, semi-annual report data show that the painkiller afentanci injection has completed clinical trials are about to be declared production.
In terms of innovative pharmaceutical projects, Enhua Pharmaceuticals is conducting clinical trials in 3 projects (D20140305-1, Pribarin resusxid capsules, DP-VPA), 1 project in the United States has completed Phase III clinical trials and declared NDA (TRV-130), new compound screening has been screened for a total of 69 preferred compounds, 4 candidate compounds, 3 candidate drugs and so on.
At present, Enhua Pharmaceuticals not only speeded up the evaluation of the consistency of various products of psychosetting drugs in the main field, but also made great efforts in the product layout of other sub-categories in the nervous system field. The Company's main business income for this year is judged to be stable growth, in January-September 2019 attributable to the shareholders of listed companies in the range of net profit changes of 486 million to 570 million yuan, the range of changes between 15.00% to 35.00%.
Psychostates: 6 approved in the first half of the year, 2 new drugs 13 generic drugs on the road Table 3: First half of 2019 approved (over-evaluated) psychostate drug situation (Source: Mienet) MED China Drug Review Database 2.0) Five psychostamides were approved in the first half of 2019, together with the oral solution approved in July this year, i.e. six products have been approved so far. National Pharmaceutical Group Yibin Pharmaceutical's oral liquor 3 types of imitation was approved for production, Qilu Pharmaceutical's O nitrogen flat-mouth chip 4 types of imitations were approved for production, are treated as if through consistency evaluation.
In terms of consistent evaluation of supplementary applications, Lipe ketone tablets, fumarate sulfur flat tablets, aliquine mouth collapse tablets have been evaluated by enterprises. Up to now, Lipe ketone tablets have reached 3 enterprises, fumarate sulfur flat tablets, aliquine mouth collapse tablets only 1 over-evaluation.
Table 4: The situation of new psychostate drugs under review in the first half of 2019 (Source: MED China Drug Review Database 2.0) Table 5: The situation of psychostate drug generics under review in the first half of 2019 (Source: MED China Drug Review Database 2.0) To date, two new drugs for psychostamides in the first half of 2019 have been approved for review, including a combination of hydrated chloral/syrup packaging and olycine oral instant film. In addition, there are 13 generic drugs in the review and approval, of which Foshan Deco pharmaceutical fumarate sulfur flat release tablets the latest status for the production site inspection, the fastest progress. (Minenet)